

Edgar Filing: CELSION CORP - Form 8-K

CELSION CORP  
Form 8-K  
April 10, 2002

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 8, 2002

Celsion Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware

000-14242

52-1256615

(State or Other Jurisdiction  
of Incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

10220-I Old Columbia Road, Columbia, Maryland

21046-1705

(Address of principal executive office)

(Zip Code)

Registrant's telephone number, including area code: (410) 290-5390

(Former Name or Former Address, if Changed Since Last Report)

ITEM 5. OTHER EVENTS

On April 8, 2002, the Company issued a press release reporting, among other things, on the filing of an Investigational New Drug Application with the Food and Drug Administration for its temperature-sensitive liposome compound in the treatment of prostate cancer. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K.

Edgar Filing: CELSION CORP - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CELSION CORPORATION

Date: April 9, 2002

By: /s/ John Mon

-----  
John Mon  
Secretary

-3-

EXHIBIT INDEX

Exhibit -----	Description -----
99.1	Press Release dated April 8 2002.